The UK has been experiencing a shortage of mitomycin 2mg, 10mg, 20mg vials for intravenous administration and 40mg for intravesical administration since late October 2019. Since the recall of Kyowa Kirin product in early November 2019 all Trusts have had to rely on unlicensed imports. Kyowa Kirin have withdrawn their marketing authorisation for Mitomycin-C and have no immediate plans to return to market with this product range.
Over the next few weeks UK licensed stock will be available from the following suppliers.
|Supplier||Product||Licensed route of administration||Estimated date available (correct as of date of comms but subject to change)||Distribution|
|Medac||40mg kit||Intravesical only||Jan 2020||Alloga|
|Accord||2mg vial||Intravesical and intravenous||w/c 26th May 2020||Mawdsleys (AAH for NI)|
|Accord||10mg vial||Intravesical and intravenous||w/c 11th May 2020||Mawdsleys (AAH for NI)|
|Accord||40mg vial||Intravenous only||w/c 4th May 2020||Mawdsleys (AAH for NI)|
|Vygoris||20mg vial||Intravesical and intravenous||w/c 27th April 2020||Mawdsleys|
Please cascade the resolution of this shortage to your Trusts who should now review the product list above and start to place orders for UK licensed stock deemed most suitable for their local requirements.